Insider trade

CEO exercised or converted 173K REGN derivative securities

Traded Dec 9, 2025 · Filed Dec 11, 2025

Regeneron PharmaceuticalsREGN

173K
Shares · @ $555.67

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Dec 9, 2025
Reporting period: Not applicable
Filed with the SEC: Dec 11, 2025

CEOOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001218629-25-000006
Filed / recorded

Dec 11, 2025, 9:23 PM UTC

Added to OQRO

Oct 2, 2026, 12:28 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

REGENERON PHARMACEUTICALS, INC.

Issuer CIK

872589

Ticker

REGN

Reporting person

Leonard S Schleifer

Relationship

Director, Officer

Officer title

Bd. Co-Chair, President & CEO

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

Dec 9, 2025

Transaction code

M

Shares / units

172,723

Price per share

$555.67

Acquired / disposed

Acquired (A)

Shares owned after

369,668

Ownership form

Direct

Amendment

No

Around the same time

9mo ago

1,500Shares · @ $374.12

Derivative exercise or conversion — not an open-market buy.

Why it stands out Official record

Director sold ~$1.2M of Regeneron Pharmaceuticals

Scheduled in advance9mo ago

9mo ago

1,500Derivative units

Derivative exercise or conversion — not an open-market buy.

Why it stands out Official record

Why it stands out

Dates, kept separate

Context

Source receipt

Around the same time

1,500Shares · @ $374.12

1,500Derivative units

Most active this month